Porges: Gilead’s hep C bash is wind­ing down and it doesn’t have a cure for the hang­over

Leerink an­a­lyst Ge­of­frey Porges has of­ten been will­ing to pre­scribe harsh med­i­cine to big bio­phar­ma play­ers that need to wake up fast. This morn­ing, he took a hard poke at a slum­ber­ing Gilead, which he be­lieves is in for a wicked fall as its mon­u­men­tal hep C fran­chise faces rapid­ly drop­ping pa­tient num­bers.

Porges down­grad­ed the stock $GILD – which dropped 1.5% this morn­ing – af­ter he turned open­ly bear­ish on hep C rev­enue fore­casts. The an­a­lyst writes:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER